NCT04607720 is a NA clinical trial of artificial-EUS-FNA in Solid Pancreatic Masses, sponsored by The Third Xiangya Hospital of Central South University.

Who is sponsoring NCT04607720?

NCT04607720 is sponsored by The Third Xiangya Hospital of Central South University.

What drugs are being tested in NCT04607720?

Interventions in NCT04607720: artificial-EUS-FNA, AI-EUS-FNA.

What condition does NCT04607720 study?

NCT04607720 studies Solid Pancreatic Masses.

Is NCT04607720 still recruiting?

NCT04607720 is currently status unknown. Last updated 29 October 2020.

Last reviewed 2020-10-29 · How we verify

NCT04607720

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Research on a Novel Deep-learning Based System in Pancreatic Mass Diagnosis

Status unknown NA Last updated 29 October 2020

What this trial tests

NA trial testing artificial-EUS-FNA in Solid Pancreatic Masses in 100 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
31 December 2021

30 June 2022

Quick facts

Lead sponsor	The Third Xiangya Hospital of Central South University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	diagnostic
Enrollment	100
Start date	1 January 2020
Primary completion	31 December 2021
Estimated completion	30 June 2022
Sites	1 location across China

Drugs / interventions tested

artificial-EUS-FNA
AI-EUS-FNA

Conditions studied

Solid Pancreatic Masses — all drugs for Solid Pancreatic Masses →

Sponsor

The Third Xiangya Hospital of Central South University

Who can join

Adults 18 to 90, any sex, with Solid Pancreatic Masses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, a single-center, prospective, self-control, and blind design was adopted.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) MASTER: A novel deep learning-based system in pancreatic mass diagnosis.
Tang A, Tian L, Gao K, Liu R, et al · · 2023 · cited 21× · PMID 36606571 · DOI 10.1002/cam4.5578

Verify or expand the search:

Other The Third Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07353307 — A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia Afte · Phase 3 · recruiting
NCT07123207 — Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Dis · NA · recruiting
NCT07034664 — IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study · recruiting
NCT07093294 — Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter · recruiting
NCT07039097 — A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resectio · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04607720 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Third Xiangya Hospital of Central South University
Last refreshed: 29 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04607720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing